Antibiotic resistance in gonorrhea bacterial cell being inhibited. There is a possibility of future enzymes (made by the bacterium) that will be able to denature and inactivate the aminoglycosides. Antibiotic resistance in gonorrhea The Gonorrhea bacterium Neisseria gonorrhoeae has developed antibiotic resistance to many antibiotics. The bacteria was first identified in 1879, although some Biblical scholars believe that references to the disease can be found as early as Parshat Metzora of the Old Testament. In the 1940s effective treatment with penicillin became available, but by the 1970s resistant strains predominated. Resistance to penicillin has developed through two mechanisms: chromasomally mediated resistance (CMRNG) and penicillinase-mediated
Quinolone antibiotic not be used as a first-line agent for community-acquired pneumonia, instead recommending macrolide or doxycycline as first-line agents. The Drug-Resistant "Streptococcus pneumoniae" Working Group recommends fluoroquinolones be used for the ambulatory treatment of community-acquired pneumonia only after other antibiotic classes have been tried and failed, or in cases with demonstrated drug-resistant "Streptococcus pneumoniae". Resistance to quinolones can evolve rapidly, even during a course of treatment. Numerous pathogens, including "Escherichia coli", commonly exhibit resistance. Widespread veterinary usage of quinolones, in particular in Europe, has been implicated. Fluoroquinolones had become the class of antibiotics most commonly prescribed to adults in 2002. Nearly